Natasha Lyonne took to X on Friday to reveal she has relapsed. The “Poker Face” star struggled with addiction to drugs and alcohol throughout the 2000s.

Primary CNS lymphoma is a rare and aggressive cancer with no FDA-approved treatments specific to the disease. While some ...

A single infusion of chimeric antigen receptor T-cell (CAR-T) therapy induced complete response or remission in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small ...

The American Society of Hematology (ASH) released guidelines on frontline management of acute lymphoblastic leukemia (ALL) in ...

FDA accepted a new drug application for tirabrutinib in relapsed or refractory PCNSL.

Please provide your email address to receive an email when new articles are posted on . The FDA approved revumenib for patients aged 1 year and older with relapsed or refractory acute myeloid leukemia ...

Because of a growing menu of effective treatments, people with multiple myeloma (MM) can now have longer disease-free periods. In many cases, though, the cancer returns (relapses) or begins to grow ...

Epcoritamab demonstrates efficacy in CAR T-naïve B-cell lymphoma patients, with 61% overall response and 45% complete response rates. Median progression-free survival and overall survival were ...

Novel targeted therapies for R/R CLL, including venetoclax plus rituximab, acalabrutinib, and zanubrutinib, have favorable safety profiles. Bendamustine plus rituximab showed a lower risk of severe ...

The ORR was 69% (95% CI, 61-76) in the zanubrutinib arm and 46% (95% CI, 34-58) in the obinutuzumab monotherapy arm. The Food and Drug Administration (FDA) has granted accelerated approval to Brukinsa ...

A childhood cancer diagnosis can be unpredictable. What will the treatment be? Will it work? Will my child relapse? Ailani Myers, 9, has relapsed seven times, but her motto remains the same. "We've ...

Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies ...